<DOC>
	<DOCNO>NCT01707628</DOCNO>
	<brief_summary>The purpose study compare number responder vaccination influenza virus vaccine different time point last dose rituximab patient lymphoma . Secondly study immune-response vaccination influenza virus vaccine , treatment rituximab relation reconstitution immune-function .</brief_summary>
	<brief_title>Response Influenza Vaccination Lymphoma Patients Treated With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Patients nonHodgkin 's lymphoma , treat rituximab ( range 612 cycle ) remission . 2 . Completion rituximab therapy last twelve month start study . 3 . Age â‰¥ 18 year . 4 . Signing informed consent . 1 . Completion rituximab therapy 78 month start study . 2 . Fever time vaccination . 3 . Previous/known allergic reaction component vaccine give .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>NHL</keyword>
	<keyword>influenza vaccination</keyword>
	<keyword>rituximab</keyword>
</DOC>